Research at the pace of decision-making
The Solution page explains Salura’s primary delivery format: Patient-Centric Impact Boards. Impact Boards are interactive research environments that organize patient and provider conversation analysis around the strategic question a team needs to answer.
Every board opens with the most important strategic truth in the data. From there, it is organized around the decision the client needs to make: where patients disengage, what language patients use, what beliefs block adoption, which barriers compound at specific journey stages, or why a support program is missing the moment when patients need it.
Common deliverables include an interactive Impact Board, a full insights report, an executive summary, and strategic implications tied to brand, launch, market access, patient support, medical affairs, or pipeline decisions.
The Solution page describes a six-step methodology: define the research question, select sources, verify stakeholder voice, code with validated qualitative frameworks, synthesize through research models, and deliver board-ready outputs.
Commercial, medical affairs, patient engagement, and strategy teams use Impact Boards to explain why messaging misses, why a launch is underperforming, what clinical data does not capture, and which unmet needs must be understood before launch or investment decisions are locked.
Patient Intelligence for Healthcare Marketers
The Services page describes the specific work Salura performs for healthcare and life sciences teams: conversation intelligence, rapid research sprints, quantitative plus qualitative analysis, patient journey mapping, HCP behavior analysis, and launch strategy support.
Conversation intelligence extracts actionable insight from patient, provider, and caregiver conversations. It identifies language, beliefs, emotional patterns, practical barriers, peer influences, and decision triggers rather than reducing patient voice to social listening or sentiment scores.
Rapid research sprints are designed for active commercial, medical, and strategic decisions where waiting for a traditional qualitative study would mean missing the planning window. Salura uses population-scale conversations, AI-assisted coding, and expert human synthesis to compress the timeline while preserving traceability.
Patient journey mapping identifies how needs and behaviors change across diagnosis, initiation, persistence, discontinuation, and long-term management. HCP behavior analysis examines what providers say to peers and how those conversations affect prescribing behavior before it appears in prescription data.
Launch strategy support helps teams identify adoption barriers before they become entrenched commercial problems, including patient resistance to switching, treatment fatigue, side-effect narratives, and educational gaps.
Decision-ready patient intelligence
The Insights page is the central content hub for Salura Health. It brings together case studies, research reports, and PCINT™ Signals so readers can understand the breadth of Salura’s work from one page.
The hub links to five case studies: breast cancer concerns shifting across the journey, GLP-1 persistence breaking down after early success, clinical trial enrollment stalling between awareness and commitment, provider conversations diverging from official prescribing narratives, and new medication underperformance explained by patient adoption signals.
The hub also points to report-style content, including women’s midlife care-seeking research and the downloadable breast cancer report. Report content is used when a topic requires a deeper research artifact or gated delivery path rather than only a narrative web case study.
PCINT™ Signals are founder or methodology perspectives that explain how Salura thinks about patient voice, research speed, patient identity, menopause care-seeking, lived experience, and the limits of conventional healthcare data.
The page is structured with filters for All, Case Studies, Blog, and Reports, so visitors can move between evidence types without leaving the hub.
Organizations turning patient knowledge into decisions
The Clients page provides traction examples and engagement patterns. It focuses on organizations and use cases rather than only research narratives.
The page highlights signed client engagements across digital health and life sciences. It names therapeutic and strategic areas including GLP-1, oncology, specialty Rx, and other areas where Salura can deploy its methodology.
Crux Health builds prescription medication journey experiences for employers and health plans. Crux partnered with Salura to understand the real-world patient behaviors driving GLP-1 discontinuation and identify a predictable drop-off window existing research had missed.
Cerula is an integrated oncology and behavioral health provider. Salura surfaced practical and emotional triggers underneath clinical milestones: where anxiety peaks, where support gaps emerge, and where care interventions could land with the most impact.
A confidential specialty pharmaceutical client used Salura to understand why a recently launched medication was underperforming despite exceeding clinical benchmarks. Patient narratives revealed well-managed disease inertia and long-term treatment fatigue, informing messaging and education strategy.
The ecosystem holds the answers. Together, we make them findable.
The Partnerships page explains Salura’s ecosystem model: every part of healthcare holds a piece of the patient story, including communities, academic studies, devices, clinics, professional researchers, and strategists.
The opportunity is fragmentation. These sources do not speak the same language and are rarely structured in a way life sciences and healthcare decision-makers can use quickly. Salura partnerships are designed to make that knowledge ethical to share, valuable to the partner, and usable by healthcare teams.
Partners can receive co-branded insight reports, a new lever for data or community knowledge they already hold, and a voice in decision-shaping moments. Co-branded reports can position a community or organization as a credible evidence source for pharma, policymakers, care delivery leaders, and funders.
Partner categories include Patient Advocacy nonprofits, Academic and Research Institutions, Professional Research Organizations, and Marketing Partners and Consultancies.
Featured examples include Glow Oncology, where Salura acts as an insights partner generating structured intelligence from patient conversations, and ISPEP, where Salura contributed to the Voice to Value initiative on the midlife care gap.
Turn your community’s stories into influence and insight
The Patient Advocacy Partnerships page is a focused page for advocacy organizations. It speaks directly to nonprofit patient advocacy groups and community leaders who hold trusted lived experience.
Patient advocacy organizations often hold years of authentic, consented, community-grounded experience. Members discuss symptoms, side effects, access barriers, diagnosis delays, treatment experiences, caregiver burden, and gaps in care.
Advocacy partners can receive co-branded insight reports, community-facing summaries, and a voice in decision-shaping moments. Community-facing summaries translate findings back to the people who contributed them, using language built for the community rather than only for industry.
The page features Glow Oncology as a Salura Patient Advocacy Partner. Glow’s mission is to bridge the gap between patients, caregivers, and the scientific community so research and drug development evolve with a Patient-Centric approach.
Patient advocacy organizations hold trust that healthcare companies cannot manufacture. Salura brings infrastructure: research methodology, AI-assisted analysis, structured outputs, and a format that healthcare decision-makers can act on.
The place where patient wisdom becomes permanent, searchable, and decision-ready
The PCINT™ Library page explains the data layer underneath Salura’s Patient-Centric Intelligence work. It focuses on the source base and compounding knowledge asset rather than only client-facing research services.
The Library includes patient stories, caregiver experiences, community conversations, public discourse, authenticated partner community data, and direct contributions. It compounds over time by condition, therapeutic area, journey stage, treatment experience, and patient population.
Most healthcare intelligence starts with structured data: claims, EHR records, surveys, clinical trial results, and market trackers. When patient stories are included, they are often reduced to sentiment analysis or topic frequency. Salura’s Library is designed to preserve context.
The Library uses direct contributions, authenticated communities, and compounding research assets. Patients and caregivers share stories on their own terms, advocacy partners contribute community-grounded lived experience, and each Impact Board adds structured insight back to the foundation.
Life sciences companies, advocacy organizations, research partners, and consultancies can connect with the Library when they need deeper patient explanation, community influence, or a qualitative layer that strengthens existing evidence.
Lived Experience
The About page explains who built Salura, why lived experience matters to the company’s methodology, and how the team’s healthcare technology background shapes its approach to Patient-Centric Intelligence™.
Founder Sue Singer is a healthcare technology executive who scaled a company to acquisition by a Fortune 100 firm and is also a two-time breast cancer warrior. Through both professional and personal experience, Sue identified a persistent gap between healthcare organizations and patient experience data.
The page frames lived experience not as a brand detail, but as a way of noticing the questions traditional research fails to ask. Patients know what it feels like to be on treatment at month four, which side effects become disruptive, what workarounds help, why they stop, and why they continue.
The Salura team includes Sue Singer, Madeline Peyton, Jess Tschirki, Zoe Freund, Shannon Barbour, Irene Sovich, Bex Abernathy, Betsy McMullin, and Borislava Marcheva.
Salura’s vision is a healthcare landscape where patient experiences are integrated into decision-making processes. The company is a certified Women-Owned Small Business (WOSB) and an ARPA-H awardee.
Ready to Discuss Your Challenge?
The Contact page is the conversion point for organizations that want to discuss a project, partnership, research question, or Salura Impact Board. It focuses on starting a conversation rather than explaining the full methodology.
Visitors are invited to contact Salura about patient intelligence research, brand strategy, launch planning, patient support design, market access questions, provider insights, clinical trial participation barriers, partnership opportunities, and custom Impact Boards.
Salura is especially relevant when a team can describe the outcome but cannot explain the behavior behind it: a medication is underperforming, patients are discontinuing, support programs are not being used, clinical trial enrollment is stalled, providers are not responding to a narrative, or a patient population is not seeking care.
A discovery conversation typically clarifies the strategic decision, stakeholder population, timeline, data sources, and desired output, such as an Impact Board, executive summary, full insights report, or stakeholder presentation support.
The listed email is marketing@salura.health. Visitors can also subscribe to receive new research, Impact Board releases, and Salura perspectives on what patient voice is revealing about healthcare decisions.
The Evolution of Patient Concerns in Breast Cancer
The Breast Cancer Report page provides access to a downloadable report titled The Evolution of Patient Concerns in Breast Cancer Journey. It is related to, but distinct from, the breast cancer case study page.
The report examines how patient concerns change across the breast cancer journey, especially the transition from diagnosis to six months post-diagnosis, where Salura’s analysis found a meaningful shift in patient concern patterns.
At diagnosis, patient conversations are dominated by acute fear and mortality concerns. By six months into treatment, those fears decline while practical concerns become more prominent: work and school disruption, housing instability, financial strain, and the logistics of surviving treatment while maintaining a life.
Standard clinical assessments can miss this concern transition. The report argues that support programs and financial toxicity interventions may be mis-timed if they are concentrated at diagnosis rather than at the later point when practical crises escalate.
The report is useful for oncology providers, patient support teams, behavioral health teams, medical affairs leaders, payers, and organizations designing breast cancer care interventions.
Privacy Policy
The Privacy Policy page is a legal and trust page. It is included in the AI-readable content bundle so crawlers understand that Salura publishes a public privacy policy, but it is not a marketing or research content page.
The policy explains how Salura handles information visitors may provide through contact forms, newsletter signups, research inquiries, gated content forms, and related site interactions.
Privacy matters to Salura because the company works with patient experience, healthcare organizations, and sensitive subject matter. The public privacy policy supports transparency for visitors, prospective clients, partners, and research participants who want to understand the company’s data practices before engaging.
The Privacy Policy is linked from the footer and sitemap. It is separate from Salura’s research methodology, client work, and PCINT™ Library pages.
Dashboard Terms of Service
The Dashboard Terms of Service page sets the legal terms under which authorized users access Salura Health's Impact Board dashboards, gated research environments, and related interactive tools.
It covers permitted use, account responsibilities, confidentiality of research outputs, intellectual property in PCINT™ analyses, restrictions on redistribution of dashboards or underlying data, and the conditions under which access may be suspended or revoked.
The terms exist because Impact Boards contain proprietary analysis derived from population-scale patient and provider conversation data and are licensed to specific client teams rather than published openly. The page is referenced from dashboard login and onboarding flows.
This page is a legal document and is separate from Salura's research methodology, case studies, and marketing content. It is included for transparency for prospective clients, partners, and dashboard users.
Breast Cancer Patient Concerns Evolve from Diagnosis to Treatment
This case study examines how breast cancer patient concerns evolve from diagnosis through six months of treatment, based on Salura Health's analysis of thousands of patient conversations using the PCINT™ Engine.
At diagnosis, 49% of patient conversations expressed acute fear focused on mortality. Six months into treatment, fear decreased to 29% but was replaced by escalating practical crises: work and school disruption (55%, up 15.8 percentage points), housing instability (46%, up 8.4 points), and financial strain (25%, up 8.7 points).
The implication for clients was that support programs, financial toxicity interventions, and counseling resources offered at diagnosis were mis-timed. They needed to be available at the six-month window when practical crises emerge. Standard clinical instruments like the PHQ series were insufficiently sensitive to this transition.
The client used these findings to realign when and how support programs are offered, protecting spend efficiency, strengthening stakeholder alignment, and surfacing a measurement gap that informed a more responsive approach to patient support.
GLP-1 Patient Persistence Breaks Down After Early Success
This case study analyzes the real-world experience of GLP-1 weight loss treatment. Salura Health's PCINT™ Engine analyzed 7,866 online patient conversations about GLP-1 medications, treatment decisions, side effects, and discontinuation.
The dominant barrier to GLP-1 persistence is cost, not clinical efficacy. 70.7% of patient mentions focused on medication cost of $500 to $1,000 or more per month. 9.2% of patients reported using compounded alternatives at $80 to $400 per month, and 4.8% accessed medications via telehealth — early signals of market migration when the branded pathway breaks down.
Patients described a specific psychological pattern: early weight loss success, followed by discontinuation due to cost or insurance barriers, weight regain, and profound psychological distress. This cycle of success-then-loss creates a treatment trauma that standard adherence counseling is not designed to address.
Patients also reported self-adjusting doses, learning about side effects like hair loss from peer networks rather than providers, and encountering knowledge gaps among prescribers on protein requirements, muscle preservation, and realistic timelines. These findings let strategy teams redirect patient support investment toward affordability and access before launch budgets were locked.
Clinical Trial Enrollment Stalls Between Awareness and Commitment
Oncology trial enrollment rates remain below 5% among eligible patients. Salura Health's PCINT™ Engine analyzed breast cancer patient conversations about clinical trial decisions to understand what additional insight peer-to-peer conversation reveals beyond formal research.
The analysis confirmed established decisional influences — desire to help others, treatment arm composition, physician recommendation, and side effects — and surfaced additional patterns: patients simultaneously hold motivated and skeptical beliefs about trials, treating cognitive ambivalence as a normal stage of the decision process rather than a communication failure.
Logistical burden — travel, time away from work and family, caregiver coordination — consistently outweighed clinical interest. Some patients actively engage with trial information without participating, acting as information brokers and community advocates. Evidence of physicians dismissing patient-initiated trial inquiries surfaced a provider–patient information asymmetry.
These findings let research teams reframe recruitment messaging around the barriers patients describe, invest in peer-to-peer communication channels as a conversion lever, and address logistical burden proactively. Awareness was not the bottleneck. Conversion was, and the barriers driving it were invisible to teams relying on clinical recruitment data alone.
Provider Conversations Diverge from Official Prescribing Narratives
This case study examines how healthcare providers discuss a specialty oncology medication in peer-to-peer settings. Salura Health's Provider-Centric Intelligence analyzed real clinical community discussions for a leading pharmaceutical company whose HCP engagement strategy was built on official prescribing guidelines and clinical data.
The analysis found that clinical focus areas providers discussed with peers differed meaningfully from the areas emphasized in official brand messaging. Specific objection patterns were circulating in provider communities that were not surfacing in field team feedback. Key peer influencers — providers whose perspectives disproportionately shaped community conversation — were identified.
Language gaps surfaced between how the brand described the mechanism of action and how providers explained it to each other. The PCINT™ Engine also identified opportunities for the medication to be repositioned within existing clinical discussions where it was not yet part of the peer dialogue.
The client used these findings to refine provider sales strategy around actual conversation patterns, address real objections in field team training before they compounded in the market, and reposition educational content to close the gap between brand language and how providers talk to colleagues.
New Medication Underperforms as Patient Adoption Signals Go Unheard
This case study examines why a newly released medication underperformed in its first six months on the market despite exceeding clinical benchmarks. Salura Health analyzed patient conversations to surface adoption signals that traditional focus groups had failed to capture.
The PCINT™ Engine identified patient resistance to switching from familiar regimens, treatment fatigue narratives circulating in patient communities, side-effect stories that shaped expectations before patients ever filled a prescription, and educational gaps that left patients without the framework needed to understand the new option's value.
Focus groups missed these patterns because they were not designed to capture the social, emotional, and peer-driven dimensions of treatment adoption. Patients were already processing the launch through peer networks, support forums, and informal discussion — and those signals were absent from the launch team's measurement system.
The client used these findings to restructure launch messaging around the actual barriers patients were naming, redirect patient education investment, and intervene in the peer narrative before adoption gaps became entrenched commercial problems. The case demonstrates why rapid patient conversation analysis belongs inside the launch decision cycle, not after it.
Capital Is Pouring Into Menopause. The Patients Haven't Arrived Yet.
This Founder Commentary by Salura Health CEO Sue Singer examines why capital pouring into the menopause category is not closing the care gap. The menopause market is having a moment — health technology companies are launching menopause solutions, employers are adding menopause benefits, and investors are writing checks — but the demand side is structurally underdeveloped.
A 2026 Mayo Clinic Proceedings study found that approximately 84% of symptomatic midlife women do not seek medical care for their symptoms. The piece argues this figure is not evidence of an access problem. It is evidence that something more fundamental is broken: most midlife women lack the cognitive representations — a name for the condition, a timeline, a theory of cause, a belief that treatment exists and will help — that make care-seeking behavior possible in the first place.
Without those representations, supply-side investments in providers, coverage, and awareness cannot land. There is no patient standing at the door. The piece reframes the menopause opportunity around identity formation rather than access, and argues that brands, investors, and employer benefits leaders need patient-language evidence of the demand-side gap before committing further spend.
Readers can explore the related MidLife Impact Board, which puts the underlying conversation analysis into a structured research environment for life sciences, digital health, and integrated care teams working in women's midlife health.
Your Data Shows What Happened. Our Job Is to Tell You Why.
This Salura Health signal makes the case that the standard commercial measurement stack — claims data, prescription fills, longitudinal cohorts, survey panels, and brand health dashboards — is excellent at describing outcomes and poor at explaining them.
Outcomes data can show that patients abandoned a therapy, delayed initiation, switched off a brand, declined a clinical trial, or disengaged from a support program. It rarely shows the belief, fear, workaround, peer influence, social context, or practical constraint that made the behavior make sense to the patient at the time. Without the why, commercial teams default to assumptions — and assumptions misallocate spend.
The piece walks through where the outcomes-only view breaks down: launch underperformance with strong clinical data, adherence drop-offs the support program cannot reach, payer conversations missing the patient story, and HCP strategies built on guidelines while peer dialogue moves in a different direction.
Salura's PCINT™ Engine pairs structured patient and provider conversation analysis with research-grade codebooks and expert synthesis to deliver the why behind the what. The signal closes with practical guidance for commercial, medical affairs, market access, and patient support leaders on where to insert conversation evidence into the decision cycle before budgets are locked.
Speed Without Sacrificing Rigor: A New Operating Model for Patient Research
This Salura Health signal describes the operating model behind PCINT™-powered research sprints — how the team delivers defensible patient and provider insights in days or weeks rather than months, and where teams should deliberately slow down to protect rigor.
The piece explains the four moves that compress the timeline without compromising research-grade outputs: starting from population-scale conversation rather than recruited samples, using AI-assisted classification under validated qualitative codebooks, applying expert human synthesis at the interpretation layer, and structuring deliverables around a specific decision rather than a generic insights report.
It is direct about where speed is the wrong goal. Stakeholder voice verification, codebook construction, and the synthesis step that turns coded conversations into strategic implications all require human judgment and should not be rushed. The signal frames this as a tradeoff to be designed for, not hidden.
The audience is commercial, medical affairs, market access, and strategy leaders who have been told that rigorous patient research takes a quarter and a six-figure budget — and who are now planning launches, payer negotiations, and trial recruitment on shorter cycles. The piece argues that the operating model, not the methodology, is what has to change.
A Founder's Note: Why Lived Experience Is a Research Methodology
In this founder's note, Salura Health CEO Sue Singer explains why she started the company: the patients she was hearing — through advocacy work, caregiving, and community — were describing experiences that the industry's traditional research instruments had no way to surface.
The piece argues that lived experience is not a soft input to be balanced against quantitative data. It is a research methodology in its own right when treated with discipline: structured listening, verified stakeholder voice, validated qualitative frameworks, and expert synthesis. Salura was built to give that methodology the same rigor and operational footing as claims analysis or survey research.
Sue describes the moments that made the gap unignorable — patients explaining decisions that contradicted the assumptions in brand strategy decks, caregivers describing barriers that never showed up in adherence data, and advocacy conversations that anticipated commercial problems quarters before they appeared in dashboards.
The note closes with the founding principle behind the PCINT™ Engine: the patient is already telling us what we need to know. The work is to listen at scale, with rigor, and translate what is being said into evidence healthcare organizations can act on before the next budget cycle.